GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Cyclically Adjusted PB Ratio

KalVista Pharmaceuticals (STU:4XC1) Cyclically Adjusted PB Ratio : 2.22 (As of Jun. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-05), KalVista Pharmaceuticals's current share price is €11.00. KalVista Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 was €4.95. KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.22.

The historical rank and industry rank for KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:4XC1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 3.69
Current: 2.07

During the past years, KalVista Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 3.69. The lowest was 0.00. And the median was 0.00.

STU:4XC1's Cyclically Adjusted PB Ratio is ranked worse than
54.7% of 660 companies
in the Biotechnology industry
Industry Median: 1.745 vs STU:4XC1: 2.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

KalVista Pharmaceuticals's adjusted book value per share data for the three months ended in Jan. 2024 was €2.351. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.95 for the trailing ten years ended in Jan. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


KalVista Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Cyclically Adjusted PB Ratio Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.29

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.29 2.45 2.05 2.70

Competitive Comparison of KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



KalVista Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.00/4.95
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, KalVista Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jan. 2024 was:

Adj_Book=Book Value per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=2.351/130.1244*130.1244
=2.351

Current CPI (Jan. 2024) = 130.1244.

KalVista Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 -28.248 100.428 -36.601
201412 -32.903 99.070 -43.217
201503 -26.125 99.621 -34.124
201506 28.113 100.684 36.333
201509 25.884 100.392 33.550
201512 24.076 99.792 31.394
201603 20.564 100.470 26.633
201606 17.049 101.688 21.817
201609 16.069 101.861 20.528
201701 3.373 102.456 4.284
201704 3.009 103.167 3.795
201707 2.386 103.278 3.006
201710 2.453 104.070 3.067
201801 2.171 104.578 2.701
201804 2.057 105.708 2.532
201807 1.786 106.324 2.186
201810 5.402 106.695 6.588
201901 5.284 106.200 6.474
201904 4.983 107.818 6.014
201907 5.100 108.250 6.131
201910 4.957 108.577 5.941
202001 4.531 108.841 5.417
202004 4.318 108.173 5.194
202007 3.622 109.318 4.311
202010 3.083 109.861 3.652
202101 2.668 110.364 3.146
202104 8.804 112.673 10.168
202107 8.462 115.183 9.560
202110 8.022 116.696 8.945
202201 7.491 118.619 8.218
202204 6.981 121.978 7.447
202207 6.584 125.002 6.854
202210 5.933 125.734 6.140
202301 5.015 126.223 5.170
202304 4.298 127.992 4.370
202307 3.676 128.974 3.709
202310 3.149 129.810 3.157
202401 2.351 130.124 2.351

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


KalVista Pharmaceuticals  (STU:4XC1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


KalVista Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (STU:4XC1) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines